Compliance with Market Abuse Regulation
Source: RNS
abrdn Diversified Income and Growth plc
LEI - 2138003QINEGCHYGW702
25 October 2024
abrdn Diversified Income and Growth plc (the "Company") announces that it is satisfied that any inside information which the Company or its Directors may have had up to today's date has previously been notified to a Regulated Information Service ("RIS").
By virtue of the points set out in (1) to (4) below, the Directors and the Company do not currently expect there to be any inside information arising in the closed period as defined by Market Abuse Regulation. The closed period will end on the date of the announcement of the Company's Annual Financial Report for the year ended 30 September 2024 (the "Annual Financial Report").
If, during the closed period leading up to the announcement of the Annual Financial Report, the Company or its Directors become aware of any inside information, such inside information will be managed in accordance with the UKLA's DTR 2.
The Company is therefore not prohibited from dealing in its own securities during the closed period.
1) the announcement on 4 October 2024 of the net asset values per share as of the close of business on 30 September 2024,
2) the Company's belief, following reasonable enquiries, that there will be no material difference between the information published on 4 October 2024 and that to be included in the forthcoming announcement of the Annual Financial Report,
3) the Company's practice of calculating net asset values per share each business day and the announcement of these net asset values to an RIS, and
4) there being no other unpublished information which constitutes price-sensitive information in respect of the Company's securities.
For further information, please contact:
Stuart Reid
abrdn Holdings Limited
Secretaries
Email: cef.cosec@abrdn.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.